Cappella Promotes Sideguard & Serial IVUS Analysis at JIM 2010

GALWAY, Ireland, Feb. 19 /PRNewswire/ -- Cappella, Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, promoted their serial IVUS analysis & Sideguard® 3.25 device during the Joint Interventional Meeting (JIM) in Rome. Gary S. Mintz, MD, Cardiovascular Research Foundation, New York, USA presented "Positive Vessel Remodeling Using Sideguard in Coronary Bifurcations" during the New Technologies 1 Symposium. Dr. Mintz highlighted that serial IVUS & OCT are ongoing in the Sideguard 3 study to confirm the initial findings of Sideguard 1 and assess stent strut coverage. The IVUS sub-study results from Sideguard 1 were published in the American Journal of Cardiology in October 2009.

The newest addition to the Sideguard portfolio, the Sideguard 3.25, was implanted successfully in a live case performed by Ralf Mueller, MD, Siegburg, Germany. According to Dr. Mueller, "We implanted the Sideguard 3.25 stent together with a 3,0mm DES in a Medina 0,1,1 LAD/D1 stenosis.  Positioning was easy and precise and IVUS demonstrated excellent scaffolding at the bifurcation. The use of the Sideguard device made this bifurcation intervention easy and predictable with an optimal acute result."

Martin B. Leon, MD, Founder & Director of Transcatheter Cardiovascular Therapeutics (TCT) and Scientific Advisory Board member of Cappella assisted with the case. Dr. Leon expressed his satisfaction with the device, "It was the first time I used the 3.25 & I was very pleased with the outcome of the case."

About Cappella, Inc.

Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. Cappella's initial product, the Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses on treating the sidebranch of diseased coronary arteries first, rather than the main vessel. More importantly, it allows the preferred stent of choice for the main vessel. An optimal stent design specific to the anatomy of the sidebranch, combined with the qualities of Nitinol now provide a dynamic solution for treating sidebranch disease. Cappella Medical Devices Ltd., Galway, Ireland is the R&D and manufacturing subsidiary of Cappella, Inc.  For more information, see: www.cappella-med.com.

SOURCE Cappella Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED